Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment

Completed

• Conditions: Psoriasis

• Registration Number: NCT05065762
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2021-09-23
• Study First Submitted QC: 2021-09-23
• Study Start: 2021-10-01
• Study First Posted: 2021-10-04
• Primary Completion: 2022-02-07
• Study Completion: 2022-02-07
• Status Verified: 2022-05
• Last Update Submitted: 2022-06-02
• Last Update Posted: 2022-06-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 232

Inclusion Criteria

• Diagnosis of moderate-to-severe Psoriasis (PsO) by physician (phase 1) or self-reported (phase 2)
• Currently taking systemic psoriasis treatment
• Japanese resident aged 20 years and older

Exclusion Criteria

• Unable or unwilling to provide informed consent
• Diagnosis of guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Distribution of clinical characteristics of PsO participants in Phase 1: Severity of PsO	At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 1: Sex	At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Weight	At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Type of occupation	At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Education	At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Age	At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Time since PsO diagnosis	At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Time on current PsO treatment	At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Level of income	At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Age	At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Current treatments for PsO	At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Residence	At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Employment status	At Baseline
Distribution of socio-demographic characteristics of PsO participants in Phase 1: Education	At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Current treatments for PsO	At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Previous treatments for PsO	At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Comorbid conditions of interest	At Baseline
Psoriasis (PsO) patient preferences of moderate-to-severe systemic treatment atrribute	Within 60 minutes of survey/interview
Distribution of clinical characteristics of PsO participants in Phase 1: Total number of previous treatments	At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Sex	At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Height	At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Residence	At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time since PsO diagnosis	At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Level of income	At Baseline
Distribution of clinical characteristics of PsO participants in Phase 1: Previous treatments for PsO	At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time on current PsO treatment	At Baseline
Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Employment status	At Baseline
Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Self-reported severity	At Baseline

Trial Locations

Locations (1)

Local Institution; 🇺🇸 Morrisville, North Carolina, United States